Form 4: Vaxcyte CEO Reports Routine Stock Transactions for Tax

Vaxcyte CEO Grant Pickering reported the surrender of shares to cover tax withholding obligations related to RSU vesting, alongside updates to his beneficial ownership.

Summary

• Grant Pickering, Chief Executive Officer and Director of Vaxcyte, Inc. (PCVX), reported transactions involving the company's common stock.
• On September 2, 2025, Mr. Pickering surrendered a total of 10,840 shares of common stock to the Issuer to cover applicable tax withholding obligations upon the vesting of Restricted Stock Units (RSUs).
• The shares were surrendered at a price of $31.56 per share.
• Following these transactions, Mr. Pickering's direct beneficial ownership of common stock is 508,264 shares.
• His beneficial ownership also includes 136,215 shares held indirectly by a trust for the benefit of his son and 136,215 shares held indirectly by a trust for the benefit of his daughter.
• The reported direct beneficial ownership includes 329 shares acquired under the Issuer's Employee Stock Purchase Plan on May 16, 2025.

Sentiment

Score: 5

Explanation: The filing is a routine compliance report for insider transactions related to RSU vesting and tax obligations, which is generally neutral in sentiment. The vesting of RSUs is positive for the executive, but the disposition for tax is a standard procedural event.

Positives

• The vesting of Restricted Stock Units (RSUs) indicates earned compensation for the CEO, reflecting performance and retention.
• The acquisition of 329 shares under the Employee Stock Purchase Plan (ESPP) on May 16, 2025, demonstrates ongoing participation in the company's equity programs and alignment with shareholder interests.

Negatives

• The disposition of 10,840 shares of common stock to cover tax withholding obligations reduces Mr. Pickering's direct beneficial ownership in the company.

Industry Context

This Form 4 filing is a routine compliance report for insider transactions, common across all publicly traded companies. It reflects standard compensation practices involving equity awards and the associated tax obligations, rather than a strategic business development or financial performance indicator for Vaxcyte within the biotechnology industry.

Related Party Transactions

• Indirect beneficial ownership of 136,215 shares each for the Reporting Person's son and daughter through separate children's trusts.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes, not indicative of a change in management's long-term view of the company.
• Employees: The vesting of RSUs and participation in ESPP are standard compensation and benefit programs, which can positively influence employee morale and retention.

Key Dates

Keywords

Vaxcyte, PCVX, Grant Pickering, CEO, Insider Trading, Form 4, Stock Transaction, RSU Vesting, Tax Withholding, Beneficial Ownership, Employee Stock Purchase Plan